Abstract:A cute myocardial infarction (AMI) is characterized by regional myocardial damage that may lead to systolic and diastolic dysfunction with a subsequent risk of left ventricular (LV) remodeling, local and systemic neurohormonal activation, and vascular dysfunction. The pathophysiology and prognosis of LV systolic dysfunction after AMI have been the focus of research for several decades. Insights from these studies have led to several therapeutic interventions that improve outcome. In addition to depressed systo… Show more
“…Incorporation of trastuzumab enhances cardiotoxicity, with published incidences for heart failure ranging from 1.7% to 16% and for asymptomatic left ventricular dysfunction ranging from 6% to 34% [4][5][6][7]. Diastolic dysfunction is an important predictor of all-cause mortality in large epidemiologic studies [8] and has been shown to play an essential role in the pathophysiology of other cardiac diseases [9,10] (e.g., ischemic heart disease, hypertensive heart disease, or myocarditis), with pathology similar to anthracycline-related cardiotoxicity [11]. Diastolic dysfunction, in this instance, contributes to the onset of heart failure and has been shown to precede the development of systolic dysfunction.…”
Introduction. Cardiotoxicity represents a major limitation for the use of anthracyclines or trastuzumab in breast cancer patients. Data from longitudinal studies of diastolic dysfunction (DD) in this group of patients are scarce. The objective of the present study was to assess the incidence, evolution, and predictors of DD in patients with breast cancer treated with anthracyclines.Methods. This analytical, observational cohort study comprised 100 consecutive patients receiving anthracycline-based chemotherapy (CHT) for breast cancer. All patients underwent clinical evaluation, echocardiogram, and measurement of cardiac biomarkers at baseline, end of anthracycline-based CHT, and at 3 months and 9 months after anthracycline-based CHT was completed. Fifteen patients receiving trastuzumab were followed with two additional visits at 6 and 12 months after the last dose of anthracycline-based CHT. A multivariate analysis was performed to find variables related to the development of DD. Fifteen of the 100 patients had baseline DD and were excluded from this analysis.
“…Incorporation of trastuzumab enhances cardiotoxicity, with published incidences for heart failure ranging from 1.7% to 16% and for asymptomatic left ventricular dysfunction ranging from 6% to 34% [4][5][6][7]. Diastolic dysfunction is an important predictor of all-cause mortality in large epidemiologic studies [8] and has been shown to play an essential role in the pathophysiology of other cardiac diseases [9,10] (e.g., ischemic heart disease, hypertensive heart disease, or myocarditis), with pathology similar to anthracycline-related cardiotoxicity [11]. Diastolic dysfunction, in this instance, contributes to the onset of heart failure and has been shown to precede the development of systolic dysfunction.…”
Introduction. Cardiotoxicity represents a major limitation for the use of anthracyclines or trastuzumab in breast cancer patients. Data from longitudinal studies of diastolic dysfunction (DD) in this group of patients are scarce. The objective of the present study was to assess the incidence, evolution, and predictors of DD in patients with breast cancer treated with anthracyclines.Methods. This analytical, observational cohort study comprised 100 consecutive patients receiving anthracycline-based chemotherapy (CHT) for breast cancer. All patients underwent clinical evaluation, echocardiogram, and measurement of cardiac biomarkers at baseline, end of anthracycline-based CHT, and at 3 months and 9 months after anthracycline-based CHT was completed. Fifteen patients receiving trastuzumab were followed with two additional visits at 6 and 12 months after the last dose of anthracycline-based CHT. A multivariate analysis was performed to find variables related to the development of DD. Fifteen of the 100 patients had baseline DD and were excluded from this analysis.
“…3) [21,22]. Показано, что рестриктив-ный тип наполнения ЛЖ у пациентов с ОИМ явля-ется мощным независимым предиктором поздней дилатации ЛЖ и сердечно-сосудистой смертности [23]. В исследовании Nijland F, et al [24] укорочение времени замедления раннего наполнения (пик E) было описано как наилучший предиктор сердечно-сосудистой смертности у пациентов, госпитализиро-ванных по поводу ОИМ.…”
Section: прогностическая значимость эхокардиографии после острого инфunclassified
“…(2) In recent studies, both left ventricle (LV) systolic and diastolic function assessed by echocardiography have been shown to predict cardiovascular events in ACS patients .However, little is known about left atrium (LA) function which is an integral part of overall cardiac function in predicting the prognosis of ACS patients. (3)(4)(5)(6) Echocardiography is now the most commonly used noninvasive tool for the assessment of cardiac anatomy and function. In addition to commonly established roles such as confirming diagnosis, etiologic work-up, complication screening, and disease monitoring, echocardiography plays an important clinical role in prognostic assessment.…”
Aim: The aim of this study is to assess the predictive value of LA function by TDI for assessment of the prognosis of patients with ST and non ST segment elevation (NSTE) myocardial infarction (MI).
Methods and Results
Conclusion: Assessment of LA function by TDI is a strong parameter in the prognosis and prediction of cardiac events in patients with ST and non ST segment elevation (NSTE) myocardial infarction (MI).
IntroductionIt is clear that studies of LA function provide new insights into the contribution of LA performance to cardiovascular disease and are promising tools for predicting cardiovascular events in a wide range of patient populations.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.